세계 염증성 장질환(IBD) 시장 규모는 2024-2030년의 예측 기간 동안 5.72%의 연평균 복합 성장률(CAGR)로 확대될 것으로 예상되며, IBD 시장은 크론병(CD) 및 궤양성 대장염(UC)을 포함한 IBD 유병률 증가, IBD 위험 요인 증가, IBD 치료제에 대한 임상 IBD 치료제의 임상시험 증가, IBD 치료제 및 진단 기기의 안전성 및 사용 편의성 향상에 대한 관심 증가 등의 요인이 긍정적인 성장을 가속하고 있으며, 이는 예측 기간(2024-2030년) 동안 IBD 시장의 괄목할 만한 매출 성장을 가져올 것으로 예상됩니다.
크론병과 궤양성 대장염을 포함한 IBD 유병률 증가는 IBD 시장 성장을 가속하는 주요 요인 중 하나입니다. 유럽 크론병 및 궤양성 대장염 협회 연합(European Federation of Crohn's and Ulcerative Colitis Associations 2022)에 따르면, 전 세계적으로 약 1,000만 명이 염증성 장 질환을 앓고 있습니다.
Crohn's &Colitis Australia 2022에 따르면, 2022년 호주에서 약 10만-16만 명이 크론병과 궤양성 대장염을 앓고 있는 것으로 추정되며, 이는 전 세계 IBD의 질병 부담에 박차를 가하고 있습니다.
흡연, 식습관 장애, 가족력, 비스테로이드성 항염증제(NSAIDs)와 같은 약물 사용, 대기오염, 스트레스, 우울증 등 IBD 발병의 위험요인이 증가함에 따라 IBD 진단 장비 및 약물에 대한 수요가 증가하여 IBD 시장 성장에 긍정적인 영향을 미치고 있습니다. 세계 각국의 흡연 인구 증가는 IBD의 전반적인 부담을 증가시킵니다. 예를 들어, Nanny State Index(NSI) 2022에 따르면 오스트리아의 흡연율은 2020년에 26.40%였습니다. 담배연기 없는 세상을 위한 재단(Foundation for a Smoke-Free World 2022)이 보고한 데이터에 따르면 2019년 브라질의 성인 흡연자는 2,040만 명에 달할 전망입니다.
이 보고서는 세계 염증성 장질환 시장을 조사했으며, 시장 개요와 함께 유형별/지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.
Inflammatory Bowel Disease (IBD) Market By Type (Diagnosis [Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Endoscopy, Blood Test, Stool Test, Immunoassays, And Others] And Treatment [Drug Class {Anti-Inflammatory Agents, Immunosuppressant, Analgesics, Antibiotics, And Others} And Surgical]), by geography, is estimated to register a remarkable CAGR during the forecast period from 2024-2030 owing to the rising number of patients suffering from inflammatory bowel disease and increasing pharmaceutical trials for IBD drugs
The global inflammatory bowel disease (IBD) market is estimated to grow at a CAGR of 5.72% during the forecast period from 2024 to 2030. The IBD market is slated to witness prosperity owing to factors such as the rising prevalence of IBD including Crohn's Disease (CD) and Ulcerative Colitis (UC), increasing risk factors for IBD, increasing number of clinical trials for IBD drugs, and the growing focus on improving the safety and usability of IBD drugs and diagnostic devices are further expected to result in the appreciable revenue growth in the IBD market during the forecast period (2024-2030).
Inflammatory Bowel Disease (IBD) Market Dynamics:
The rising prevalence of IBD including Crohn's Disease and Ulcerative Colitis is one of the major factors driving the growth of the IBD market. According to the European Federation of Crohn's and Ulcerative Colitis Associations 2022, worldwide around 10 million people are suffering from inflammatory bowel disease.
As per Crohn's & Colitis Australia 2022, it was estimated that around 100,000 to 160,000 people were living with Crohn's disease and Ulcerative Colitis in Australia in 2022, thus adding to the global disease burden of IBD.
The rising number of risk factors including smoking, poor eating habits, family history, use of drugs such as Non-steroidal Anti-inflammatories (NSAIDs), air pollution, stress, and depression among others for IBD development is also going to increase the demand for diagnostic devices and medications for IBD, positively impacting the market growth for IBD. The increasing rate of smoking population in multiple countries around the world increases the overall burden of IBD. For instance, as per the Nanny State Index (NSI) 2022, the rate of people smoking in Austria was 26.40% in 2020. As per the data reported by Foundation for a Smoke-Free World 2022, there were 20.4 million adult smokers in Brazil in 2019.
Also, the use of NSAIDs which are often taken for the treatment and management of several inflammatory conditions is highly associated with the occurrence of IBD. NSAIDs may trigger the disease activity in both Crohn's disease and Ulcerative Colitis. These drugs can result in a frequent and early relapse of IBD. Thereby, accelerating the demand for IBD drugs and diagnostic devices.
The increasing number of pharmaceutical trials for inflammatory bowel disease is likely to assist the growth of the inflammatory bowel disease market. For example, in May 2022, the pivotal, Phase III LUCENT-2 study of Eli Lilly and Company, involving patients with Ulcerative Colitis (UC) who were treated with mirikizumab for 12 weeks witnessed statistically superior and clinically significant improvements at one year compared to placebo across all important secondary endpoints, including bowel urgency severity, and the primary endpoint of clinical remission.
Also, in March 2022, Pfizer Inc. announced positive Phase III results from the study of etrasimod which is an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator, in development, for the treatment of moderately to severely active Ulcerative Colitis (UC).
However, side effects associated with IBD drugs and stringent regulatory challenges for IBD drugs and diagnostic devices may act as a restraint in the growth of the inflammatory bowel disease market.
The inflammatory bowel disease market reported a short period of restraint in the market growth owing to the implementation of the lockdown as a necessary step to stop the spread of COVID-19 infection. This led to a decline in the development and manufacturing of IBD drugs owing to a shortage of raw materials. Also, the manufacturing and supply of diagnostic devices for IBD were affected. Moreover, due to shifted focus on first treating patients with COVID-19 infection, the diagnosis and treatment of IBD-suspected patients were halted. However, with the resumption of activities across industries including the healthcare and pharmaceutical sector, there has been a rising demand for the IBD owing to the resumption of activities. The post-COVID scenario is going to be uplifting for the IBD market during the forecast period from 2024-2030.
Inflammatory Bowel Disease (IBD) Market Segment Analysis:
IBD Market by Type (Diagnosis [Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Endoscopy, Blood Test, Stool Test, Immunoassays, and Others] and Treatment [Drug Class {Anti-Inflammatory Agents, Immunosuppressant, Analgesics, Antibiotics, and Others} and Surgical]), Geography (North America, Europe, Asia-Pacific, and Rest of the World)
Based on the type segment of the IBD market, the endoscopy category under-diagnosis is projected to register a significant growth in revenue in the IBD market during the forecast period (2024-2030).
This can be ascribed to the advantages associated with the various endoscopic methods in the diagnosis, treatment, and management of inflammatory bowel disease.
Endoscopic methods including colonoscopy, esophagogastroduodenoscopy, sigmoidoscopy, and capsule endoscopy are the key diagnostic methods utilized for the accurate diagnosis of IBD. Diagnosis through these methods helps in the easy differentiation of Crohn's disease (CD) with that from Ulcerative Colitis (UC).
Ileocolonoscopy which is colonoscopy with ileoscopy is considered the gold standard method for the detection and diagnosis of inflammatory bowel disease. Through ileocolonoscopy, the most severely or commonly affected areas of the bowel in patients with IBD can be easily visualized.
Esophagogastroduodenoscopy is highly recommended in pediatric patients in whom IBD is suspected and it helps to establish a definitive diagnosis for both Crohn's disease (CD) and Ulcerative Colitis (UC).
Sigmoidoscopy assists in the examination of IBD in the colon and rectum. Capsule endoscopy offers visualization of the entire length of the small bowel in suspected IBD patients in a comparatively less invasive manner. For example, PillCam(TM) SB 3 by Medtronic is a minimally invasive capsule endoscopy system with an ingestible camera in a capsule that allows visualization of the small bowel and assists in the diagnosis of Crohn's disease.
Therefore, considering the advantages associated with endoscopic methods and their growing popularity among the end-users, this product category is expected to generate considerable revenue thereby pushing the overall growth of the global IBD market during the forecast period.
North America is expected to dominate the overall Inflammatory Bowel Disease (IBD) Market:
Among all the regions, North America is expected to lead in revenue generation in the global IBD market. This can be ascribed to the increasing prevalence of IBD across the region, and a highly potent market in terms of product development and launches, initiatives by government and non-government organizations for IBD patients, and the local presence of key market players among other factors in the region.
The rising number of cases of IBD in the region is one of the major factors driving the growth of the inflammatory bowel disease market. For instance, as per the Centers for Disease Control and Prevention 2022, about 3 million people are living with IBD in the United States. As per the same source, around 80,000 children are expected to be suffering from IBD in the US. This, therefore, indicates the growing need for diagnostic tools and technologies as well as medications for proper diagnosis, treatment, and management of the disease.
The rising number of initiatives by the government and non-government organizations such as research funding in the region is another possible factor affecting the growth of the IBD market. Crohn's & Colitis Foundation is a non-profit organization involved in sponsoring basic and clinical research happening in relation to inflammatory bowel disease. For instance, In May 2022, Progenity, Inc., a biotechnology company, received funding from the Crohn's & Colitis Foundation's IBD Ventures program to further develop Progenity's first-in-class oral Drug Delivery System (DDS) for delivery of targeted therapeutics for IBD.
Earlier, in January 2022, to potentially create the first clinical lab test to forecast disease course in young patients with Crohn's disease and response to therapy, the Crohn's & Colitis Foundation partnered with LifeArc, an independent medical research charity that promotes translation of early science into health care treatments or diagnostics. The clinicians would benefit from a predictive test that could properly predict which kids may experience issues and which patients will benefit from anti-TNF therapy.
Hence, the above-mentioned factors are expected to bolster the growth of the IBD market in the United States during the forecast period.
Inflammatory Bowel Disease (IBD) Market Key Players:
Some of the key market players operating in the IBD market include Thermo Fisher Scientific, JSR Life Sciences, LLC, Novartis AG, AbbVie Inc., Janssen Global Services, LLC, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb, Pfizer Inc., Johnson & Johnson Services, UCB S.A., Belgium, F. Hoffmann-La Roche AG, Ferring B.V., Prometheus Laboratories, Actim Oy, DiaSorin S.p.A., BUHLMANN, Quidel Corporation, ALPCO, CERTEST BIOTEC, Medtronic, and others.
Recent Developmental Activities in the Inflammatory Bowel Disease (IBD) Market:
In March 2022, AbbVie received the US Food and Drug Administration (FDA) approval for RINVOQ® (upadacitinib) for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients.
In May 2022, Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has approved Zeposia® for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
Key Takeaways from the Inflammatory Bowel Disease (IBD) Market Report Study
Target Audience who can be benefited from this Inflammatory Bowel Disease (IBD) Market Report Study
Frequently Asked Questions for the Inflammatory Bowel Disease (IBD) Market:
IBD associated with chronic inflammation in the gastrointestinal tract (GI) includes Crohn's disease and Ulcerative Colitis and is characterized by symptoms such as abdominal pain, diarrhea, loss of appetite, mucus or blood in stool, and others.
The global inflammatory bowel disease (IBD) market is estimated to grow at a CAGR of 5.72% during the forecast period from 2024 to 2030.
The IBD market is slated to witness prosperity owing to factors such as the rising prevalence of inflammatory bowel disease, increasing risk factors for IBD, increasing number of pharmaceutical trials for IBD drugs, and the growing focus on improving the safety, affordability, and usability of IBD drugs and diagnostic devices are further expected to result in the appreciable revenue growth in the IBD market during the forecast period (2024-2030).
Some of the key market players operating in the IBD market include Thermo Fisher Scientific, JSR Life Sciences, LLC, Novartis AG, AbbVie Inc., Janssen Global Services, LLC, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb, Pfizer Inc., Johnson & Johnson Services, UCB S.A., Belgium, F. Hoffmann-La Roche AG, Ferring B.V., Prometheus Laboratories, Actim Oy, DiaSorin S.p.A., BUHLMANN, Quidel Corporation, ALPCO, CERTEST BIOTEC, Medtronic, and others.
North America is expected to dominate the overall IBD during the forecast period, 2024 to 2030. This can be ascribed to the increasing research and development activities w.r.t. to inflammatory bowel disease in the region, the increasing number of patients suffering from Crohn's disease and Ulcerative Colitis, high-tech medical facilities, government initiatives, and a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region.